HPV vaccine reduces cervical cancer risk by 87%, but uptake remains poor
The first study to effectively demonstrate the impact of human papillomavirus (HPV) vaccination on cervical cancer incidence has been recently…
All articles by Globaldata Healthcare
Globaldata Healthcare
Global has decades of experience in being the trusted, gold standard intelligence provider to leading pharmaceutical brands, manufacturers, and suppliers, helping them to make faster, more informed decisions
-
-
Breast cancer awareness month: Remembering the burden of this disease
According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the…
-
US leads actively recruiting clinical trials for Covid-19
As new strains of COVID-19 continue to drive new cases globally, companies and institutions have continued development of interventions for…
-
Potential FDA Approval on the Way for Amylyx’s AMX0035 in ALS Ahead of Time
On September 15, Amylyx Pharmaceuticals announced that its bid to submit a new drug application (NDA) for its amyotrophic lateral…
-
Resumed trials continue to increase further
Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due…
-
Seelos Therapeutics’ intranasal ketamine offers promise in treating suicidality
On July 6, Seelos Therapeutics announced that the first patient has been dosed in the second part of their registrational,…
-
ASCO 2021: LAG-3 is now a validated target in Melanoma
At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, results from the Phase…
-
ASCO 2021: Compelling data For Ciltacabtagene Autoleucel in multiple myeloma
At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, Johnson & Johnson (J&J)…
-
Microbiome therapeutics rising as potential immuno-oncology agents
Clinical data and industry partnerships have fueled a shift in perception of the microbiome-based therapeutic market from nascent to developing,…
-
Interim Data from UK Com-COV study suggest higher reactogenicity but remain inconclusive
The Oxford-led Phase II Com-COV trial is investigating immune responses in patients who have been given heterologous prime-boost vaccine schedules…